688331 荣昌生物
已收盘 05-06 15:00:01
资讯
新帖
简况
每周股票复盘：荣昌生物（688331）Q1净利增229.06%
证券之星 · 05-02
每周股票复盘：荣昌生物（688331）Q1净利增229.06%
荣昌生物（688331）2026年一季报简析：营收净利润同比双双增长
证券之星 · 04-30
荣昌生物（688331）2026年一季报简析：营收净利润同比双双增长
荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈
老虎资讯综合 · 04-28
荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈
荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%
证券之星 · 04-27
荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%
汇添富基金增持荣昌生物(09995)7.9万股 每股作价约113.78港元
智通财经网 · 04-24
汇添富基金增持荣昌生物(09995)7.9万股 每股作价约113.78港元
百济、信达、贝达、荣昌生物...盈利Biotech增至17家
赛柏蓝 · 04-21
百济、信达、贝达、荣昌生物...盈利Biotech增至17家
万家基金黄兴亮旗下万家行业优选一季报最新持仓，重仓荣昌生物
证券之星 · 04-21
万家基金黄兴亮旗下万家行业优选一季报最新持仓，重仓荣昌生物
每周股票复盘：荣昌生物（688331）获艾伯维6.5亿美元首付款
证券之星 · 04-19
每周股票复盘：荣昌生物（688331）获艾伯维6.5亿美元首付款
港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%
智通财经 · 04-16
港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%
智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率
智通财经 · 04-16
智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率
荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款
智通财经 · 04-15
荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款
港股创新药板块午后持续走高，荣昌生物涨近10%
每日经济新闻 · 04-15
港股创新药板块午后持续走高，荣昌生物涨近10%
4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股
证券之星 · 04-13
4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股
港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市
智通财经 · 04-13
港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市
【机构调研记录】九泰基金调研荣昌生物
证券之星 · 04-13
【机构调研记录】九泰基金调研荣昌生物
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
智通财经 · 04-13
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
美股速递 · 04-10
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
证券日报 · 04-10
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
荣昌生物：维迪西妥单抗新适应症获批准
每日经济新闻 · 04-10
荣昌生物：维迪西妥单抗新适应症获批准
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
证券之星 · 04-07
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":127.7,"timestamp":1778050801000,"preClose":129.31,"halted":0,"volume":10638219,"delay":0,"changeRate":-0.0125,"floatShares":163000000,"shares":564000000,"eps":2.2885,"marketStatus":"已收盘","change":-1.61,"latestTime":"05-06 15:00:01","open":129,"high":130.32,"low":127.5,"amount":1371000000,"amplitude":0.0218,"askPrice":127.7,"askSize":143,"bidPrice":127.68,"bidSize":2,"shortable":0,"etf":0,"ttmEps":2.2885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":5,"adr":0,"adjPreClose":129.31,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778031000000,1778038200000],[1778043600000,1778050800000]],"highLimit":142.24,"lowLimit":116.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":18.35,"roa":"--","peRate":55.800743,"roe":"8.68%","epsLYR":1.29,"committee":-0.318182,"marketValue":72084000000,"turnoverRate":0.0652,"status":1,"afterMarket":{"amount":47249,"volume":370,"close":127.7,"buyVolume":2630,"sellVolume":0,"time":1778052837558,"indexStatus":"已收盘 05-06 15:30:00","preClose":129.31},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":97.7,"timestamp":1778054890009,"preClose":97.2,"halted":0,"volume":3148512,"delay":0,"premium":"-33.45"},"floatMarketCap":20827000000},"requestUrl":"/m/hq/s/688331/","defaultTab":"news","newsList":[{"id":"2632493046","title":"每周股票复盘：荣昌生物（688331）Q1净利增229.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632493046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632493046?lang=zh_cn&edition=full","pubTime":"2026-05-02 01:26","pubTimestamp":1777656371,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，荣昌生物报收于129.31元，较上周的133.03元下跌2.8%。本周，荣昌生物4月28日盘中最高价报139.98元。股本股东变化截至2026年3月31日，荣昌生物股东户数为1.97万户，较2月28日增加2264户，增幅达12.97%。业绩披露要点荣昌生物2026年一季报显示，主营收入6.56亿元，同比增长24.76%；归母净利润3.28亿元，同比上升229.06%；扣非净利润-3499.1万元，同比改善86.12%；负债率为46.66%，毛利率为82.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688331","LU1064131003.USD","LU2488822045.USD","BK0239","LU2148510915.USD","BK1583","LU1969619763.USD","BK1161","09995","LU1064130708.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578474","title":"荣昌生物（688331）2026年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631578474?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:54","pubTimestamp":1777503282,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期荣昌生物发布2026年一季报。根据财报显示，荣昌生物营收净利润同比双双增长。截至本报告期末，公司营业总收入6.56亿元，同比上升24.76%，归母净利润3.28亿元，同比上升229.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137868631","title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1137868631","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137868631?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:48","pubTimestamp":1777366101,"startTime":"0","endTime":"0","summary":"4月28日，$荣昌生物(09995)$公告称，2026年第一季度实现营业收入6.56亿元，同比增长24.76%；归属于上市公司股东的净利润为3.28亿元，同比扭亏为盈。业绩变动主要系商业化产品销售收入持续增加，以及产品技术授权导致研发投入减少，认股权证公允价值变动所致。小财注：公司Q1净利润3.28亿，2025年Q4净利润12.6亿，据此计算，Q1净利润环比下降73%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1583","LU2328871848.SGD","BK1161","BK1574","LU1969619763.USD","LU1064130708.USD","LU2148510915.USD","688331","BK0239","09995","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397093","title":"荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397093","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:04","pubTimestamp":1777298696,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，荣昌生物报收于135.05元，较前一交易日上涨1.52%，最新总市值为762.33亿元。近日，荣昌生物发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00参加由上海证券交易所组织举办的上述集体业绩说明会，通过上证路演中心网络文字互动方式与投资者交流。公司将就2025年度经营成果、财务状况等投资者关注的问题进行回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1583","01477","BK0239","09995","BK1574","LU2488822045.USD","LU1064131003.USD","BK1161","688331","BK1191","LU2328871848.SGD","LU1969619763.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009846","title":"汇添富基金增持荣昌生物(09995)7.9万股 每股作价约113.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009846","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629009846?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:09","pubTimestamp":1777028987,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，汇添富基金增持荣昌生物(09995)7.9万股，每股作价113.7788港元，总金额约为898.85万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1969619763.USD","LU1064130708.USD","LU2328871848.SGD","LU2148510915.USD","LU2488822045.USD","09995","BK1161","688331","BK1574","EWH","BK0239","LU1064131003.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703962","title":"百济、信达、贝达、荣昌生物...盈利Biotech增至17家","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703962","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703962?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:54","pubTimestamp":1776772440,"startTime":"0","endTime":"0","summary":"Biotech似乎终于集体熬到了“上岸”时刻。其中最受关注的自然是百济和信达。百济成立15年后，2025年归母净利润达到14.22亿元；信达生物实现近8.14亿元净利润，正式扭亏为盈。百济神州、微芯生物、迈博药业、信达生物、上海谊众、贝达药业、艾力斯等公司的产品销售收入占比都超过90%。荃信生物2025年净利润3.07亿元，8.07亿元总营收里，7.23亿元来自BD收益。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-04-21/doc-inhvhmhw6117856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","BK4588","LU2328871848.SGD","LU1064131003.USD","LU1969619763.USD","BK4585","LU2148510915.USD","XBI","688331","09995","BK4581","BK0239","LU1064130708.USD","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377970","title":"万家基金黄兴亮旗下万家行业优选一季报最新持仓，重仓荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629377970?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:23","pubTimestamp":1776720184,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日万家基金旗下黄兴亮管理的万家行业优选混合型基金(LOF)公布一季报，近1年净值增长率21.98%。与上一季度相比，该基金前十大重仓股新增科大讯飞；其中荣昌生物持仓占比8.84%，为该基金第一大重仓股；圣邦股份等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100010049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2328871848.SGD","LU2488822045.USD","09995","BK0239","688331","BK1574","BK1583","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275136","title":"每周股票复盘：荣昌生物（688331）获艾伯维6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275136","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275136?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:30","pubTimestamp":1776540626,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，荣昌生物报收于150.11元，较上周的135.48元上涨10.8%。本周，荣昌生物4月16日盘中最高价报156.79元，股价触及近一年最高点。荣昌生物当前最新总市值847.34亿元，在生物制品板块市值排名1/51，在两市A股市值排名235/5198。公司公告汇总荣昌生物制药（烟台）股份有限公司宣布，已收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款。该协议于2026年3月10日生效，艾伯维获得了RC148在大中华区以外地区的开发、生产和商业化独家权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2148510915.USD","BK0239","LU1064130708.USD","BK1583","BK1161","LU1969619763.USD","688331","LU2488822045.USD","LU1064131003.USD","09995","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627254292","title":"港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627254292","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627254292?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:01","pubTimestamp":1776301266,"startTime":"0","endTime":"0","summary":"【重大事项】宁德时代(03750)拟投资 300 亿元设立全资子公司 打造新能源矿产平台美格智能(03268)拟投资3亿元于AI研发及先进制造产业项目并签署投资协议力勤资源(02245)：印尼镍矿政策变动不影响正常经营 与合作伙伴保持良好合作关系确保Obi项目稳定运行中远海能(01138)拟10.18亿元建造两艘巴拿马型原油轮荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"05d74946e1a2924d42dd26ed36b9a988","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0823038988.USD","LU2506952337.HKD","LU0359201612.USD","LU0449515922.USD","LU1188198961.HKD","HK0000181138.USD","LU1978683503.SGD","LU2298322129.HKD","LU0345776255.USD","LU1008478684.HKD","IE00B3M56506.USD","SG9999001689.USD","LU1064131003.USD","LU0320764755.SGD","LU2348773727.SGD","LU2476274720.SGD","LU0320764599.SGD","LU0235996351.USD","00300","LU0593848301.USD","300433","IE0003795394.USD","LU2153592121.USD","SG9999000327.SGD","LU0164880469.USD","BK1618","LU0051755006.USD","LU2424517915.HKD","LU0561508036.HKD","LU0326948709.USD","LU1993786604.SGD","LU0214875030.USD","BK1610","600115","LU0499858602.USD","LU1152091754.HKD","LU1769817096.USD","LU1242518857.USD","01093","LU0327786744.USD","LU0039217434.USD","SGXZ81163826.USD","LU0651947912.USD","LU2298064838.USD","HK0000165453.HKD","LU0828237510.HKD","LU0797268264.HKD","LU0611395673.USD","SG9999000459.SGD","SBHMY","LU2399975544.HKD","LU1152091168.USD","LU2097828557.USD","BK1193","LU0594300179.USD","LU0228659784.USD","LU1051769294.HKD","IE0034224299.USD","LU0326950275.SGD","LU0244354667.USD","LU0054450605.USD","LU1831875114.USD","LU0149721374.USD","LU0516423091.SGD","BK1521","LU0823426480.USD","LU0164865239.USD","LU0164872284.USD","LU2294711473.HKD","LU1102505929.USD","LU0509642566.USD","LU1868838027.USD","LU2226246903.HKD","LU0169518387.USD","LU1861219969.SGD","LU0823413660.USD","LU1880383366.USD","01177","LU0359201885.HKD","LU0043850808.USD","03908","02556","LU0140636845.USD","LU0469268626.HKD","LU0124384867.USD","02186","06656","LU1939255532.USD","LU0188438112.USD","SGXZ49509284.SGD","LU0823397103.USD","LU0828238088.HKD","LU1048596156.SGD","LU1807302812.USD","IE0032431581.USD","01810","LU2477742899.HKD","LU0455707207.USD","BK1523","BK1535","LU0143863198.USD","LU2348774022.SGD","IE00B29SXG58.USD","SG9999001846.SGD","81810","LU0269904917.USD","LU0441854154.USD","LU1861214812.USD","300750","LU0821914370.USD","LU1328277881.USD","LU1719994722.HKD","LU1769817179.HKD","02245","LU0405327148.USD","LU2580892789.USD","LU0128522157.USD","LU1820825898.SGD","LU0210526637.USD","LU0405327494.USD","LU0708995583.HKD","HK0000286598.CNH","LU1720050803.USD","LU0261950470.USD","BK1502","SG9999002463.SGD","LU1102505762.USD","LU1781817850.SGD","LU1048588211.SGD","LU1997245177.USD","LU2506952410.USD","LU2039709279.SGD","LU0823426308.USD","LU0607220059.USD","LU0634319403.HKD","LU2097828631.EUR","LU2357125470.USD","LU1794554557.SGD","LU0106959298.USD","LU0067412154.USD","LU0117841782.USD","09995","LU0181495838.USD","LU1051768304.USD","LU1146622755.USD","LU1251922891.USD","LU0823039010.USD","LU0314109678.HKD","02038","EVS.SI","LU0823040885.USD","XIACY","LU0463099449.HKD","LU0823397285.USD","LU0107464264.USD","LU2045819591.USD","BK1166","LU0456846285.SGD","LU0251143458.SGD","LU1960683339.HKD","LU1997245094.SGD","IE00BZ199S13.USD","IE00BD6J9T35.USD","01138","LU2495084118.USD","LU0029875118.USD","LU0302445910.USD","LU1039395188.USD","LU1580142542.USD","LU0823041008.USD","LU0345775950.USD","LU2328871848.SGD","LU0231483743.USD","LU0084288322.USD","LU0254981946.USD","LU2506952253.HKD","LU0370786039.SGD","LU1770034418.SGD","LU0106259558.USD","LU1303224171.USD","688331","LU0417516738.SGD","LU1956131251.USD","LU2580892862.HKD","LU1961090484.USD","000333","LU2506951792.HKD","BK4526","LU0049853897.USD","LU0531971595.HKD","IE00B8HQ1Z84.USD","BK1149","LU0823414551.USD","LU1981816686.USD","LU1655091616.SGD","LU0543330483.HKD","LU0211977185.USD","BK1116","LU2449936058.SGD","LU0348827113.USD","LU1979443071.USD","LU0651946864.USD","LU0823414478.USD","LU2476274308.USD","LU1515016050.SGD","LU2097828805.USD","LU0672654166.SGD","LU2125910849.SGD","LU0572944931.SGD","LU1255011170.USD","06936","LU1969619763.USD","LU0456827905.SGD","LU1023057109.AUD","LU0499858438.USD","LU0516422440.USD","LU0052750758.USD","LU0165289439.USD","LU0348816934.USD","LU0106252389.USD","LU0516422952.EUR","LU0516423174.USD","LU0328353924.USD","002881","SG9999001903.USD","CCOZY","600026","LU0048388663.USD","LU0359202008.SGD","LU0501845795.SGD","603906","BK4141","LU0149534421.HKD","LU0588546209.SGD","LU0823437842.USD","LU2153591404.USD","LU1105468828.SGD","LU0724618433.USD","LU1868837565.USD","LU0540923850.HKD","LU1934453819.USD","IE00B543WZ88.USD","LU0979878070.USD","LU0348735423.USD","LU2257852520.SGD","LU0417516902.SGD","LU0880133367.SGD","LU0605514214.HKD","02465","LU2275660780.HKD","LU1282648689.USD","LU0918141705.HKD","HXXD.SI","LU0449509016.USD","00753","BK1575","06613","00670","LU0871576103.HKD","IE00B5MMRT66.SGD","LU0531970944.HKD","LU1721428347.USD","002352","LU0143863784.USD","LU0259732245.USD","LU0700851271.USD","LU0011963245.USD","IE00BPRC5H50.USD","SG9999003461.SGD","LU2249611893.SGD","LU1242518931.SGD","LU1880383440.USD","LU0650527681.SGD","BK0224","LU0312595415.SGD","LU0307460666.USD","LU0505663152.USD","BK1506","BK4585","03268","LU0594300419.USD","LU2360107325.USD","LU2152927971.USD","LU0348805143.USD","LU2097828714.EUR","BK4519","LU0828237940.HKD","LU0047713382.USD","LU0502904849.HKD","LU0675040207.SGD","LU2238339852.HKD","BK1607","LU0072913022.USD","LU3063872942.SGD","LU0348814723.USD","BK1615","LU2289578879.USD","SG9999001093.SGD","LU0048575426.USD","SG9999002828.SGD","LU2294711713.HKD","LU1808992512.USD","LU0918141887.USD","LU2778985437.USD","LU2125910500.SGD","LU1997244956.HKD","HK0000181112.HKD","LU0516422366.SGD","LU1323998911.USD","03750","LU2087589342.USD","LU0823413587.USD","601898","LU0132412106.USD","01898","LU2148510915.USD","LU0072462343.USD","601111","LU1813983027.USD","IE0003851619.USD","601995","LU0192582467.USD","LU1064130708.USD","LU0348825331.USD","LU1770036033.HKD","FXCNY","LU0048580855.USD","IE00B8L5B284.USD","LU2097828474.EUR","BK1589","LU1481107354.HKD","SG9999014674.SGD","LU2242644610.SGD","08279","02298","MIUmain","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627256069","title":"智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率","url":"https://stock-news.laohu8.com/highlight/detail?id=2627256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627256069?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:41","pubTimestamp":1776296486,"startTime":"0","endTime":"0","summary":"探索词元交易等新型交易模式，构建以词元为基础，可量化、可定价的数据集价值体系。将进出口银行的境外贷款杠杆率由3上调至3.5。截至收盘，暗盘交易显示报价578港元，较招股价324.2港元上涨78.29%，每手100股，不计手续费，每手赚25380港元。归属于上市公司股东的净利润为207","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0067412154.USD","LU1152091754.HKD","LU2328871848.SGD","BK4585","LU1993786604.SGD","BK1147","688331","BK1516","BK1583","LU1807302812.USD","03908","LU0359201885.HKD","BK1610","BK1564","02245","BK4588","01177","300750","08279","03750","BK1501","06656","LU0359202008.SGD","BK1116","LU0359201612.USD","601995","BK1190","LU0880133367.SGD","LU1960683339.HKD","BK1161","LU1152091168.USD","LU1969619763.USD","09995","SG9999002828.SGD","BK1574","SBHMY","LU1023057109.AUD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627340291","title":"荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2627340291","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627340291?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:46","pubTimestamp":1776242798,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，于2026年1月12日，本公司与艾伯维就RC148签署独家授权许可协议，该协议于2026年3月10日生效。根据协议，艾伯维将获得RC148在大中华区以外地区的开发、生产和商业化的独家权利。本公司董事会欣然宣布，本公司已就RC148的独家授权许可协议从艾伯维收到6.5亿美元的首付款。目前双方的合作进展顺利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064130708.USD","BK1574","09995","688331","LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","BK1161","BK1583","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540852","title":"港股创新药板块午后持续走高，荣昌生物涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540852","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540852?lang=zh_cn&edition=full","pubTime":"2026-04-15 13:10","pubTimestamp":1776229832,"startTime":"0","endTime":"0","summary":"4月15日，港股创新药板块午后持续走高，荣昌生物涨近10%，君实生物涨超5%，诺诚健华、信达生物、复星医药跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705735216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705735216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","BK4588","LU2328871848.SGD","VXUS","LU1064131003.USD","159992","LU1064130708.USD","06978","BK1574","LU2148510915.USD","BK4585","BK1161","BK0239","688331","LU1969619763.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627349433","title":"4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627349433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627349433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:13","pubTimestamp":1776067998,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日荣昌生物涨7.98%，收盘报146.29元，换手率7.54%，成交量12.3万手，成交额17.51亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级10家；过去90天内机构目标均价为148.5。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共48家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300020025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD","09995","BK1161","BK1583","688331","BK0239","160916","LU1064130708.USD","LU2488822045.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627348834","title":"港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2627348834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627348834?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:02","pubTimestamp":1776045779,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物(09995)涨超4%，截至发稿，涨4.43%，报110.7港元，成交额2.35亿港元。消息面上，4月10日，荣昌生物宣布，公司自主研发的抗体偶联（ADC）药物维迪西妥单抗（RC48，爱地希®）一项新适应症获国家药品监督管理局正式批准上市，用于联合特瑞普利单抗治疗HER2表达的局部晚期或转移性尿路上皮癌患者，HER2表达定义为HER2免疫组织化学检查结果为1+、2+或3+。荣昌生物表示，这标志着维迪西妥单抗的治疗范围从后线成功拓展至一线，为中国HER2表达晚期尿路上皮癌患者带来了全新的治疗选择，也成为全球首个获批一线治疗晚期尿路上皮癌的HER2-ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09995","BK4588","IPOS","BK1583","LU1064131003.USD","BK4585","LU2148510915.USD","BK1574","VXUS","LU1969619763.USD","LU2488822045.USD","LU1064130708.USD","BK0239","688331","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627610285","title":"【机构调研记录】九泰基金调研荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2627610285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627610285?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:01","pubTimestamp":1776038472,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月10日披露的机构调研信息，九泰基金近期对1家上市公司进行了调研，相关名单如下：1）荣昌生物 调研纪要：2025年营业收入32.51亿元，同比增长89.36%；综合毛利率87.3%，同比增长6.9个百分点；研发费用12.19亿元，同比下降20.9%；净利润7.1亿元，实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300000934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK1161","LU2328871848.SGD","BK0239","BK1583","LU2148510915.USD","LU2488822045.USD","09995","BK1574","LU1064131003.USD","688331","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627389104","title":"智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2627389104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627389104?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:18","pubTimestamp":1776035912,"startTime":"0","endTime":"0","summary":"牌照于今日生效。伊美第三轮谈判已结束 双方存在严重分歧总台记者当地时间12日获悉，伊朗与美国在伊斯兰堡举行的又一轮会谈已结束。伊朗方面消息称，伊朗与美国代表团在谈判中仍存在一些严重分歧。美伊谈判21小时未达成协议。盛宝银行首席投资策略师 Charu Chanana 表示，美伊谈判无果而终是一次倒退。美英担忧 AI 暴露金融业漏洞Anthropic 发布 AI 模型 Mythos 预览版，美国政府日前召集一批银行高管紧急开会，讨论相关问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7d08dbda469a470286c6f9b045c09156","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1791807156.HKD","06166","WFC","LU1861558580.USD","CCUP","06185","BK1161","601869","CRCG","BK4588","CRCA","AMZN","C","09995","03317","CRCD","00005","01773","BK1596","CRCO","06680","AMD","HSBC","LU1861220207.SGD","BK4023","BK1228","LU2328871848.SGD","06088","BK1556","BAC","LUMN","ICRC","LU1969619763.USD","BK1583","06869","688331","LU0106831901.USD","688185","LU2360107671.USD","01729","BK4585","BK1500","603083","LU1861559042.SGD","NVDA","AVGO","06960","300748","LU1668664300.SGD","LU1861217088.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191656067","title":"荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191656067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191656067?lang=zh_cn&edition=full","pubTime":"2026-04-10 22:36","pubTimestamp":1775831783,"startTime":"0","endTime":"0","summary":"荣昌生物制药股份有限公司宣布，其创新药物维迪西妥单抗（Disitamab Vedotin）的新药上市申请已正式获得批准，适应症为HER2表达阳性的尿路上皮癌。这一重要进展为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","BK0239","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192923","title":"荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192923","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626192923?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:28","pubTimestamp":1775820480,"startTime":"0","endTime":"0","summary":"证券日报网讯4月10日，荣昌生物在互动平台回答投资者提问时表示，公司2025年第四季度利润增长主要系公司在第四季度确认了与VorBiopharmaInc.就RC18达成的授权许可首付款收入，该笔收入在第四季度完成相关合同义务履行并确认。同时，核心产品泰它西普、维迪西妥单抗的销售收入亦保持良好增长态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701423440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09995","LU2328871848.SGD","VOR","BK4139","BK0239","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","BK1574","LU2488822045.USD","LU1064131003.USD","BK1161","688331","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193856","title":"荣昌生物：维迪西妥单抗新适应症获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193856","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193856?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:56","pubTimestamp":1775811411,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，荣昌生物(688331.SH)公告称，公司近日收到国家药监局核准签发的《药品注册证书》，维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701182236.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701182236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","BK1583","09995","BK0239","LU2488822045.USD","BK1574","LU1064131003.USD","BK1161","688331","LU2328871848.SGD","LU1969619763.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625936395","title":"荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625936395","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625936395?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:07","pubTimestamp":1775552830,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，荣昌生物报收于141.66元，较前一交易日下跌4.99%，最新总市值为799.64亿元。近日，荣昌生物披露《华泰联合证券有限责任公司关于荣昌生物制药（烟台）股份有限公司2025年度持续督导现场检查报告》。公告显示，华泰联合证券作为保荐机构，于2026年3月31日对荣昌生物2025年度的公司治理、内部控制、信息披露、独立性、募集资金使用、关联交易、对外担保、重大对外投资及经营状况等情况进行了现场检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","LU1969619763.USD","09995","688331","BK1574","LU2488822045.USD","BK0239","LU2328871848.SGD","LU2148510915.USD","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778073725321,"stockEarnings":[{"period":"1week","weight":-0.0414},{"period":"1month","weight":0.0042},{"period":"3month","weight":0.2646},{"period":"6month","weight":0.3046},{"period":"1year","weight":1.5515},{"period":"ytd","weight":0.6623}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19720人(较上一季度增加12.97%)","perCapita":"8270股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}